<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02858804</url>
  </required_header>
  <id_info>
    <org_study_id>IIT2015007-EC-1</org_study_id>
    <nct_id>NCT02858804</nct_id>
  </id_info>
  <brief_title>EDOCH Alternating With DHAP for New Diagnosed Younger MCL</brief_title>
  <acronym>BDH-MCL01</acronym>
  <official_title>EDOCH Alternating With DHAP Regimen Combined Rituximab or Not to Treat New Diagnosed Younger (Age≤65 Years) Mantle Cell Lymphoma in China: A Multicentre Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Hematology &amp; Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Hematology &amp; Blood Diseases Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to:

        1. determine the efficiency of EDOCH (etoposide,dexamethasone,doxorubicin, cyclophosphamide
           and vincristine) alternating with DHAP (cisplatin, cytarabine and dexamethasone) regimen
           combined with rituximab or not in young mantle cell lymphoma patients (age≤65 years);

        2. determine the efficiency of rituximab and thalidomide plus prednisone as maintenance
           regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrolled patients will receive EDOCH (etoposide,dexamethasone,doxorubicin, cyclophosphamide
      and vincristine) ±R /DHAP(cisplatin, cytarabine and dexamethasone) ±R alternating
      chemotherapy. If a partial remission or better response achieves, patients will be
      recommended to receive autologous stem cell transplantation as consideration therapy or
      another two cycles EDOCH ±R /DHAP±R chemotherapy (based on patient's choice). Patients with
      less than partial remission (PR) response will quit this study. After treatments finished,
      maintenance therapy with rituximab or thalidomide plus prednisone will be given less than two
      years. The determination of maintenance regimens is dependent on patients choices.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>up to 36 months</time_frame>
    <description>the time interval between diagnosis and disease progression or death or last follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete remission</measure>
    <time_frame>up to 6 months</time_frame>
    <description>measure with normal serum immunofixation electrophoresis and normal bone marrow feature, and without symptoms and enlarged organs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 36 months</time_frame>
    <description>time interval between diagnosis and death or last follow-up</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg/m2, IV, d1-4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg/m2, IV, d1-4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg/d, d1-5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vincristine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.4 mg/m2, IV, d1-4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>750 mg/m2 ,d5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2g/m2, q12h, d1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg/ m2,IV, d1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>375 mg/m2 IV, d1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50-150mg/d, po, d1-28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5mg/Kg, po, qod</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>50 mg/m2, IV d1-4</description>
    <arm_group_label>Etoposide</arm_group_label>
    <other_name>VP-16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>10 mg/m2, IV, d1-4</description>
    <arm_group_label>Doxorubicin</arm_group_label>
    <other_name>adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>30 mg/d, d1-5</description>
    <arm_group_label>Dexamethasone</arm_group_label>
    <other_name>Dex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>0.4 mg/m2, IV, d1-4</description>
    <arm_group_label>Vincristine</arm_group_label>
    <other_name>VCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>750 mg/m2 ,d5</description>
    <arm_group_label>Cyclophosphamide</arm_group_label>
    <other_name>CTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>2g/m2, q12h, d1</description>
    <arm_group_label>Cytarabine</arm_group_label>
    <other_name>Ara-c</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>100mg/ m2,IV, d1</description>
    <arm_group_label>Cisplatin</arm_group_label>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2 IV, d1</description>
    <arm_group_label>Rituximab</arm_group_label>
    <other_name>R</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>50-150mg/d, po, d1-28</description>
    <arm_group_label>Thalidomide</arm_group_label>
    <other_name>Thal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>0.5mg/Kg, po, qod</description>
    <arm_group_label>Prednisone</arm_group_label>
    <other_name>Pred</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age≤65 years

          -  diagnosis with mantle cell lymphoma

          -  Ann Arbor stage II,III or IV

          -  ECOG≤1 or if ECOG≥2 but recover after pretreatment.

        Exclusion Criteria:

          -  with centre neural system involvement

          -  serious complications such as uncontrolled diabetes, gastric ulcer or other serious
             angiocardiopathy determined by the physician

          -  HIV positive or active HBV infection or other uncontrolled systematic infection

          -  clinical central nervous dysfunction

          -  serious surgery within 30 days

          -  pregnancy or baby nursing period or un-contracepted child bearing period woman.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuhua Yi, Doc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blood disease hospital, Chinese Academic Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shuhua Yi, Doc</last_name>
    <phone>86-22-23909106</phone>
    <email>yishuhua@ihcams.ac.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lugui Qiu, Doc</last_name>
    <phone>86-22-23909172</phone>
    <email>qiulg@ihcams.ac.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shuhua Yi</name>
      <address>
        <city>Tianjin</city>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuhua Yi, Doc</last_name>
      <phone>86-22-23909106</phone>
      <email>yishuhua@ihcams.ac.cn</email>
    </contact>
    <contact_backup>
      <last_name>Lugui Qiu, Doc</last_name>
      <phone>86-22-23909172</phone>
      <email>qiulg@ihcams.ac.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2016</study_first_submitted>
  <study_first_submitted_qc>August 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2016</study_first_posted>
  <last_update_submitted>August 3, 2016</last_update_submitted>
  <last_update_submitted_qc>August 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Hematology &amp; Blood Diseases Hospital</investigator_affiliation>
    <investigator_full_name>Yi Shuhua</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>mantle cell lymphoma</keyword>
  <keyword>EDOCH</keyword>
  <keyword>DHAP</keyword>
  <keyword>maintenance therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

